查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595116

骨質疏鬆症藥物市場：按藥物類型、給藥途徑和應用分類 - 全球預測 2025-2030

Osteoporosis Drugs Market by Drug Type (Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy), Route of Administration (Injectable, Oral), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年骨質疏鬆藥物市值為83.2億美元，預計2024年將達87.7億美元，複合年成長率為5.60%，到2030年將達到121.9億美元。

骨質疏鬆症藥物市場專注於骨質疏鬆症的治療和預防，骨質疏鬆症是一種以骨量減少和骨折風險增加為特徵的疾病。該市場包括多種藥物治療，包括雙磷酸鹽、選擇性雌激素受體調節（SERM）、副甲狀腺素（PTH）類似物和單株抗體。世界人口老化推動了對這些藥物的需求，尤其是停經後女性，骨質疏鬆症的治療可以提高生活品質並降低與骨折治療相關的醫療費用。應用範圍橫跨醫院、診所和居家醫療，涵蓋治療和預防。最終使用者主要是老年人，尤其是超過閉經的女性。

主要市場統計
基準年[2023] 83.2億美元
預測年份 [2024] 87.7億美元
預測年份 [2030] 121.9億美元
複合年成長率（%） 5.60%

影響市場成長的關鍵因素包括提高意識和診斷率、藥物處方和管理的進步以及支持政府醫療保健政策。醫療基礎設施正在迅速改善的新興市場也存在機會。開發副作用較少、給藥方案較簡單的藥物具有巨大的潛力。然而，它也存在很大的局限性，包括高昂的藥物成本、嚴格的法律規範以及抑制患者依從性的潛在副作用。另一個挑戰是醫療政策和報銷問題因地區而異。

提供成長機會的創新研發領域包括聯合治療的開發、個人化醫療方法以及遠距患者管理的遠距遠端醫療整合。生物技術和基因治療的進步有望成為新的治療平台。該市場表現出競爭性，主要企業大力投資研究，以減少現有藥物的副作用並提高其有效性。鼓勵公司專注於研發策略聯盟和合作，開拓開拓的區域市場，並強調病患教育計畫以提高市場滲透率。市場擴張也應優先考慮解決現有的限制，例如最佳化給藥系統和提高製劑的安全性。

市場動態：揭示快速發展的骨質疏鬆症藥物市場的關鍵市場洞察

供需因素的動態交互作用正在改變骨質疏鬆藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口的成長和生活方式的改變影響骨骼健康
    • 提高停經後婦女對骨質疏鬆症照護和骨質疏鬆症盛行率的認知
  • 市場限制因素
    • 骨質疏鬆治療藥物專利到期的擔憂
  • 市場機會
    • 活性化醫療機構的產品開發和研究活動
    • 各機構研究經費快速增加
  • 市場挑戰
    • 與骨質疏鬆症藥物相關的副作用，如噁心、胃灼熱和潰瘍

波特的五力策略工具駕馭骨質疏鬆症藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨質疏鬆藥物市場的外部影響

外部宏觀環境因素在塑造骨質疏鬆藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解骨質疏鬆症治療藥物市場的競爭狀況

對骨質疏鬆症藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣骨質疏鬆藥物市場供應商績效評估

FPNV定位矩陣是評估骨質疏鬆藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪骨質疏鬆症藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，骨質疏鬆症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口的增加和生活習慣的改變正在影響骨骼健康
      • 意識提升停經後婦女骨質疏鬆症照護和骨質疏鬆症發生率的意識
    • 抑制因素
      • 對骨質疏鬆症藥物專利到期的擔憂
    • 機會
      • 醫療機構的新產品開發和研究活動
      • 各組織增加研究經費
    • 任務
      • 與骨質疏鬆症藥物相關的副作用，如噁心、胃灼熱和潰瘍
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章：依藥物類型分類的骨質疏鬆症治療市場

  • 雙磷酸鹽
  • 抑鈣素
  • 副甲狀腺素治療
  • 活化因數配體抑制劑
  • 選擇性雌激素抑制劑調變器

第7章骨質疏鬆症治療藥物市場：依給藥途徑

  • 可注射的
  • 口服

第8章骨質疏鬆症治療藥物市場：依應用分類

  • 原發性骨質疏鬆症
  • 續發性骨質疏鬆症

第9章 北美及南美骨質疏鬆藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區骨質疏鬆藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲骨質疏鬆藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 宣佈為骨質疏鬆症研究提供新資金
    • 世衛組織和歐洲骨質疏鬆症協會宣布達成合作協議，以幫助預防全球骨質疏鬆症和骨折。
    • FDA核准Timlos 用於治療男性骨質疏鬆症
    • Evenity（romosozumab）治療骨折高風險停經後婦女的嚴重骨質疏鬆症獲得了 CHMP 的正面意見
    • 安進 (Amgen) 以 278 億美元收購 Horizo​​n，以擴大罕見疾病產品線。
    • 中外製藥與東和製藥推出骨質疏鬆症治療藥物“Edirol片”
    • Akums Drugs 與 Microcore Research 合作生產 NESM補充品。
    • Lupin 已與 Irom 達成協議，在日本進行停經後治療藥物的臨床試驗和銷售。
    • Farmanovia 收購羅氏 Rocaltrol 拓展中國業務
    • Timros 製造商 Radius Health 以 8.9 億美元的價格出售給投資公司。
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alembic Pharmaceuticals Ltd.
  • Alkem Laboratories Ltd.
  • Amgen, Inc.
  • Apotex Inc.
  • Century Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Cubit Healthcare
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F.Hoffmann La Roche AG
  • GlaxoSmithKline PLC
  • Hetero Healthcare Ltd.
  • Intas Pharmaceuticals Ltd
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co AG
  • Midas Pharma GmbH
  • Mylan NV by Viatris Inc.
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Polpharma
  • Pulse Pharmaceuticals
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vintage Labs Pvt. Ltd.
Product Code: MRR-AD36CD8980EF

The Osteoporosis Drugs Market was valued at USD 8.32 billion in 2023, expected to reach USD 8.77 billion in 2024, and is projected to grow at a CAGR of 5.60%, to USD 12.19 billion by 2030.

The market for osteoporosis drugs is primarily focused on the treatment and prevention of osteoporosis, a condition characterized by reduced bone mass and increased fracture risk. This market encompasses a variety of pharmaceutical treatments, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH) analogs, and monoclonal antibodies. The necessity for these drugs is driven by the global aging population, notably among post-menopausal women, making the treatment of osteoporosis critical for improving quality of life and reducing healthcare costs related to fracture treatment. Application extends across hospitals, clinics, and home healthcare settings, targeting both therapeutic and preventive care. The end-users predominantly are older adults, particularly women beyond the menopausal age.

KEY MARKET STATISTICS
Base Year [2023] USD 8.32 billion
Estimated Year [2024] USD 8.77 billion
Forecast Year [2030] USD 12.19 billion
CAGR (%) 5.60%

Key factors influencing market growth include increasing awareness and diagnosis rates, advances in drug formulation and administration, and supportive government healthcare policies. Opportunities also lie in emerging markets where healthcare infrastructure is rapidly improving. The development of drugs with fewer side effects and more convenient dosing regimens presents significant potential. However, significant limitations include high drug costs, stringent regulatory frameworks, and potential side effects that may impede patient adherence. Additionally, varying healthcare policies and reimbursement issues across regions pose challenges.

Innovation and research areas offering growth opportunities include the development of combination therapies, personalized medicine approaches, and the integration of telemedicine for remote patient management. Advances in biotechnology and gene therapy hold the promise of novel treatment platforms. The market exhibits a competitive nature with prominent players investing heavily in research to mitigate the existing drug side effects and improve efficacy. Companies are recommended to focus on strategic alliances and collaborations for R&D, exploring untapped regional markets, and emphasizing patient education programs to enhance market penetration. Addressing the existing limitations by optimizing drug delivery systems and enhancing drug formulation safety profiles should also be prioritized to bolster market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoporosis Drugs Market

The Osteoporosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising elderly population coupled with changing lifestyle habits impacting bone health
    • Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
  • Market Restraints
    • Concerns over patent expiration of osteoporosis drugs
  • Market Opportunities
    • Emerging product development and research activities in healthcare organizations
    • Proliferation in the research funding from various organizations
  • Market Challenges
    • Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Osteoporosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoporosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoporosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoporosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoporosis Drugs Market

A detailed market share analysis in the Osteoporosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoporosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoporosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoporosis Drugs Market

A strategic analysis of the Osteoporosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoporosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alembic Pharmaceuticals Ltd., Alkem Laboratories Ltd., Amgen, Inc., Apotex Inc., Century Pharmaceuticals Ltd., Cipla Ltd., Cubit Healthcare, Dr. Reddy's Laboratories, Eli Lilly and Company, F.Hoffmann La Roche AG, GlaxoSmithKline PLC, Hetero Healthcare Ltd., Intas Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd., Merck & Co AG, Midas Pharma GmbH, Mylan N.V. by Viatris Inc., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Polpharma, Pulse Pharmaceuticals, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., and Vintage Labs Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoporosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and Selective Estrogen Inhibitors Modulator.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Application, market is studied across Primary Osteoporosis and Secondary Osteoporosis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
      • 5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over patent expiration of osteoporosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging product development and research activities in healthcare organizations
      • 5.1.3.2. Proliferation in the research funding from various organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Osteoporosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Bisphosphonates
  • 6.3. Calcitonin
  • 6.4. Parathyroid Hormone Therapy
  • 6.5. Rank Ligand Inhibitors
  • 6.6. Selective Estrogen Inhibitors Modulator

7. Osteoporosis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Osteoporosis Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Primary Osteoporosis
  • 8.3. Secondary Osteoporosis

9. Americas Osteoporosis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Osteoporosis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Osteoporosis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. New funding for osteoporosis research announced
    • 12.3.2. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
    • 12.3.3. FDA Clears Tymlos for Osteoporosis in Men
    • 12.3.4. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
    • 12.3.5. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
    • 12.3.6. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
    • 12.3.7. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
    • 12.3.8. Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan.
    • 12.3.9. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche
    • 12.3.10. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alembic Pharmaceuticals Ltd.
  • 3. Alkem Laboratories Ltd.
  • 4. Amgen, Inc.
  • 5. Apotex Inc.
  • 6. Century Pharmaceuticals Ltd.
  • 7. Cipla Ltd.
  • 8. Cubit Healthcare
  • 9. Dr. Reddy's Laboratories
  • 10. Eli Lilly and Company
  • 11. F.Hoffmann La Roche AG
  • 12. GlaxoSmithKline PLC
  • 13. Hetero Healthcare Ltd.
  • 14. Intas Pharmaceuticals Ltd
  • 15. Macleods Pharmaceuticals Ltd.
  • 16. Merck & Co AG
  • 17. Midas Pharma GmbH
  • 18. Mylan N.V. by Viatris Inc.
  • 19. Natco Pharma Ltd.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Polpharma
  • 23. Pulse Pharmaceuticals
  • 24. Steris Healthcare Pvt. Ltd.
  • 25. Sun Pharmaceutical Industries Ltd
  • 26. Taj Pharmaceuticals Ltd.
  • 27. Teva Pharmaceutical Industries Ltd.
  • 28. Vintage Labs Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. OSTEOPOROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OSTEOPOROSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OSTEOPOROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OSTEOPOROSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RANK LIGAND INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN INHIBITORS MODULATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PRIMARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SECONDARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023